Симбикорт: испытание временем

Θεματικοί όροι: SMART therapy, budesonide/formoterol, будесонид/формотерол, Симбикорт Турбухалер, asthma, anti-inflammatory bronchodilator, chronic obstructive pulmonary disease, ингаляционная терапия, inhalation therapy, metered-dose powder inhaler, противовоспалительный бронхолитик, Symbicort Turbuhaler, бронхиальная астма, хроническая обструктивная болезнь легких, дозированный порошковый ингалятор, режим SMART

Dosing powder inhaler Turbuhaler, its characteristics and a place among other inhalation devices ; Дозированный порошковый ингалятор Турбухалер: особенности и место среди других ингаляционных устройств доставки

Συγγραφείς: S. N. Avdeev, С. Н. Авдеев

Πηγή: PULMONOLOGIYA; № 1 (2012); 117-122 ; Пульмонология; № 1 (2012); 117-122 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2012-0-1

Θεματικοί όροι: Турбухалер, inhalation devices, Turbuhaler, дозированный порошковый ингалятор

Περιγραφή αρχείου: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/27/26; Laube B.L., Janssens H.M., de Jongh F.H. et al; European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37: 1308–1331.; Lavorini F., Magnan A., Dubus J.C. et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir. Med. 2008; 102: 593–604.; Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемые при терапии заболеваний дыхательных путей. Рус. мед. журн. 2002; 10 (5): 255–261.; Wetterlin K. Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm. Res. 1988; 5: 506–508.; Wetterlin K.I.L. Design and function of Turbuhaler. In: Newman S.P., Moren F., Crompton G.K., eds. A new concept in inhalation therapy. London: Medicom; 1987.; Johnsen C.R., Weeke E.R. Turbuhaler: a new device for dry powder terbutaline inhalation. Allergy 1988; 43: 392–395.; Frijlink H.W., De Boer A.H. Dry powder inhalers for pulmonary drug delivery. Expert Opin. Drug Deliv. 2004; 1: 67–86.; Smith I.J., Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther. 2003; 16: 79–95.; Telko M.J., Hickey A.J. Dry powder inhaler formulation. Respir. Care 2005; 50: 1209–1227.; Авдеев С.Н. Порошковые ингаляторы. Атмосфера. Пульмонол. и аллергол. 2004; 4: 36–42.; Borgstrom L., Bisgaard H., O'Callaghan C., Pedersen S. Drypowder inhalers. In: Bisgaard H., O'Callaghan C., Smaldone G., ed. Drug delivery to the lung. New York: Marcel Dekker Inc.; 2002. 421–448.; Borgstrom L., Bondesson E., Moren F. et al. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur. Respir. J. 1994; 7: 69–73.; Pedersen S., Hansen O.R., Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch. Dis. Child. 1990; 65: 308–310.; Newman S.P., Busse W.W. Evolution of dry powder inhaler design, formulation, and performance. Respir. Med. 2002; 96: 293–304.; Lofdahl C.G., Arvidsson P., Bondesson E., Friberg K. Higher potency of salbutamol when given via Turbuhaler than via pressurized metered dose inhaler (pMDI). Allergy Clin. Immunol. News 1994; 6 (Suppl. 2): 383.; Matusiewicz S.P., Bollert F.G.E., Dewar M. et al. Ipratropium bromide given by Turbohaler® is more potent than when given by pressurized metered-dose inhaler (MDI). Thorax 1995; 50: 469.; Borgstrom L., Derom E., Stahl E. et al. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am. J. Respir. Crit. Care Med. 1996; 153: 1636–1640.; Derom E., Thorsson L. Factors affecting the clinical outcome of aerosol therapy. In: Bisgaard H., O'Callaghan C., Smaldone G., ed. Drug delivery to the lung. New York: Marcel Dekker Inc.; 2002. 143–171.; Everard M.L., Dolovich M.B. In vivo measurements of lung dose. In: Bisgaard H., O'Callaghan C., Smaldone G. (Ed). Drug delivery to the lung. New York: Marcel Dekker Inc.; 2002. 173–209.; Newman S.P., Moren F., Trofast E. et al. Terbutaline sulphate Turbuhaler effect of inhaled flow rate on drug deposition and efficacy. Int. J. Pharm. 1991; 74: 209–213.; Newman S.P. A comparison of lung deposition patterns between different asthma inhalers. J. Aerosol Med. 1995; 8 (Suppl. 3): S21–S27.; Thorsson L., Kenyon C., Newman S.P., Borgstrom L. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int. J. Pharm. 1998; 168: 119–127.; Thorsson L., Edsbacker S., Conradson T.-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurised metered dose inhaler P-MDI. Eur. Respir. J. 1994; 7: 1839–1844.; Thorsson L., Edsbacker S., Kallen A., Lofdahl C-G. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br. J. Clin. Pharmacol. 2001; 52: 529–538.; Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J. Allergy Clin. Immunol. 1998; 101: S434–S439.; Olsson B. Can in vitro measurements predict the lung deposition of dry-powder inhalers? J. Aerosol Med. 1997; 10: S13–S16.; Olsson B. Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers. J. Aerosol Med. 1995; 8 (Suppl. 3): 13–19.; Dolovich M.B. New propellant-free technologies under investigation. J. Aerosol Med. 1999; 12 (Suppl. 1): S9–S17.; Bisgaard H., Klug B., Sumby B.S., Burnell P.K. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur. Respir. J. 1998; 11: 1111–1115.; Granlund K.M., Asking L., Lindblad T. et al. An in-vitro comparison of budesonide / formoterol and fluticasone / salmeterol in dry powder inhalers. Eur. Respir. J. 2000; 16 (Suppl. 31): 455s.; Fyrnys B., Stang N., Wolf-Heuss E. Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device. Curr. Opin. Pulm. Med. 2001; 7 (Suppl. 1): S7–S11.; Srichana T., Martin G.P., Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur. J. Pharm. Sci. 1998; 7: 73–80.; Pavkov R., Singh D., Reitveld I. Concept1 (a new single dose dry powder inhaler) peak inspiratory flow rate study with COPD patients. Respir. Drug Deliv. 2008; 3: 683–686.; Svartengren K., Lindestad P., Svartengren M. et al. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am. J. Respir. Crit. Care Med. 1995; 152: 32–37.; Borgstrom L. On the use of dry powder inhalers in situations perceived as constrained. J. Aerosol. Med. 2001; 14: 281–287.; McNeill R., Malcom G., Rhind Brown W. A comparison of expiratory and inspiratory flow rates in health and chronic pulmonary disease. Thorax 1959; 14: 25–31.; Brown P.H., Ning A.C., Greening A.P. et al. Peak inspiratory flow through Turbuhaler in acute asthma. Eur. Respir. J. 1995; 8: 1940–1941.; Dewar M.H., Jamieson A., McLean A., Crompton G.K. Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease. Respir. Med. 1999; 93: 342–344.; van den Broek K.M., Wielders P.L.M.L., Creemers J.P.H.M., Smeenk F.W.J.M. Efficacy of formoterol Turbuhaler in the emergency treatment of patients with obstructive airway diseases. Respir. Med. 2008; 102: 579–585.; Nana A., Youngchaiyud P., Charoenratanakul S. et al. Highdose inhaled budesonide may substitute for oral therapy after an acute asthma attack. J. Asthma 1998; 35: 647–655.; Springer C., Stahl E., Schachter J., Avital A. Terbutaline given via Turbuhaler and in nebulised form in children with acute asthma. Eur. J. Clin. Res. 1996; 8: 163–169.; Phanareth K., Laursen L.C. Bricanyl Turbuhaler versus nebuliser in the treatment of patients with acute severe airways obstruction. Eur. Respir. J. 1999; 14 (Suppl. 30): 61s.; Balanag V.M., Yunus F., Yang P.-C., Jorup C. Efficacy and safety of budesonide / formoterol compared with salbutamol in the treatment of acute asthma. Pulm. Pharmacol. Ther. 2006; 19: 139–147.; Cazzola M., D'Amato M., Califano C. et al. Formoterol as dry powder oral inhalation compared with salbutamol metereddose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin. Ther. 2002; 24: 595–604.; Selroos O., Borgstrom L., Ingelf J. Use of dry powder inhalers in acute exacerbations of asthma and COPD. Ther. Adv. Respir. Dis. 2009; 3: 81–91.; Lindblat T., Granlund K.M., Rollwage U., Trofast E. Delivery chatracteristics of SymbicortТ TurbuhalerТ containing both budesonide and formoterol. Am. J. Respir. Crit. Care Med. 2001; 165: A863.; Lindsay D.A., Russell N.L., Thompson J.E. et al. A multicentre comparison of the efficacy of terbutaline Turbuhaler and salbutamol pressurized metered dose inhaler in hot, humid regions. Eur. Respir. J. 1994; 7: 342–345.; van der Palen J., Klein J.J., Schildkamp A.M. Comparison of a new multidose powder inhaler (Diskus / Accuhaler) and the Turbuhaler regarding preference and ease of use. J. Asthma 1998; 35: 147–152.; Wettengel R., Laurikainen K., Silvasti M. et al. Therapeutic equivalence and acceptability of two multidose powder inhalers in the treatment of asthma. Respiration 2000; 67: 77–82.; Lenney J., Innes J.A., Crompton G.K. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir. Med. 2000; 94: 496–500.; Serra-Batlles J., Plaza V., Badiola C., Morejion E. Inhalation Devices Study Group. Patient perception and acceptability of multidose dry powder inhalers: a randomized crossover comparison of Diskus / Accuhaler with Turbuhaler. J. Aerosol Med. 2002; 5: 59–64.; van Spiegel P.I., Jenner F. A patient preference study comparing Turbuhaler with Discus, two multi-dose dry powder inhaler devices. Br. J. Clin. Res. 1997; 8: 33–35.; Giner J., Torrejon M., Ramos A. et al. Patient preference in the choice of dry powder inhalers. Arch. Bronconeumol. 2004; 40: 106–109.; Tordera M.P., Viejo J.L., Sanchos J. et al. Assessment of patient satisfaction and preferences with inhalers in asthma with the FSI-10 Questionnaire. Arch. Bronconeumol. 2008; 44: 346–352.; https://journal.pulmonology.ru/pulm/article/view/27

Διαθεσιμότητα: https://journal.pulmonology.ru/pulm/article/view/27
https://doi.org/10.18093/0869-0189-2012-0-1-117-122